Halozyme Therapeutics, Inc.

Equities

HALO

US40637H1095

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
38.57 ^USD	+0.29%		-0.18%	+4.36%

Apr. 25	Halozyme Therapeutics, Inc. Announces the Election of Mahesh Krishnan, M.D. to its Board of Directors	CI
Apr. 18	Halozyme Therapeutics Insider Sold Shares Worth $768,390, According to a Recent SEC Filing	MT

Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Twelve Months Ended December 31, 2023

January 17, 2024 at 08:11 am EST

Halozyme Therapeutics, Inc. provided earnings guidance for the twelve months ended December 31, 2023. The company estimates 2023 revenue will be in the range of $827 million to $832 million, net income will be in the range of $292 million to $297 million and GAAP Diluted EPS will be in the range of $2.18 to $2.21.

Latest news about Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. Announces the Election of Mahesh Krishnan, M.D. to its Board of Directors	Apr. 25	CI
Halozyme Therapeutics Insider Sold Shares Worth $768,390, According to a Recent SEC Filing	Apr. 18	MT
Halozyme Therapeutics Insider Sold Shares Worth $839,100, According to a Recent SEC Filing	Mar. 13	MT
Transcript : Halozyme Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 10:45 AM	Mar. 13
Transcript : Halozyme Therapeutics, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 02:50 PM	Mar. 05
HC Wainwright Adjusts Halozyme Therapeutics Price Target to $50 From $48, Maintains Buy Rating	Feb. 21	MT
Halozyme Therapeutics Q4 Adjusted Earnings, Revenue Rise; Reiterates 2024 Guidance	Feb. 21	MT
Transcript : Halozyme Therapeutics, Inc., Q4 2023 Earnings Call, Feb 20, 2024	Feb. 20
Tranche Update on Halozyme Therapeutics, Inc.'s Equity Buyback Plan announced on December 9, 2021.	Feb. 20	CI
Earnings Flash (HALO) HALOZYME THERAPEUTICS Reports Q4 EPS $0.82, vs. Street Est of $0.83	Feb. 20	MT
(HALO) HALOZYME THERAPEUTICS Forecasts Fiscal Year 2024 Revenue Range $915M - $985M	Feb. 20	MT
Earnings Flash (HALO) HALOZYME THERAPEUTICS Reports Q4 Revenue $230M, vs. Street Est of $231.1M	Feb. 20	MT
Halozyme Therapeutics Guides For 2024 EPS of $3.55-$3.90, vs CIQ Analyst Consensus of $3.64/Share	Feb. 20	MT
Halozyme Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 20	CI
Halozyme Therapeutics, Inc. announces an Equity Buyback for $750 million worth of its shares.	Feb. 20	CI
Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	Feb. 20	CI
Halozyme Therapeutics, Inc. authorizes a Buyback Plan.	Jan. 31	CI
Halozyme Announces Takeda Receives European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy	Jan. 29	CI
Halozyme Therapeutics Insider Sold Shares Worth $720,000, According to a Recent SEC Filing	Jan. 18	MT
Halozyme Therapeutics Says Argenx Gets Japan's Approval for Vyvdura to Treat Certain Generalized Myasthenia Gravis Patients	Jan. 18	MT
Goldman Sachs Cuts Halozyme Therapeutics' Price Target to $40 From $45, Keeps Neutral Rating	Jan. 18	MT
Halozyme Announces Argenx Receives Approval in Japan for Vyvdura®? Co-Formulated with Enhanze®? for Generalized Myasthenia Gravis	Jan. 18	CI
HC Wainwright Cuts Halozyme Therapeutics Price Target to $48 From $61, Maintains Buy Rating	Jan. 18	MT
Transcript : Halozyme Therapeutics, Inc. - Special Call	Jan. 17
Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Twelve Months Ended December 31, 2023	Jan. 17	CI

Chart Halozyme Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Companyâs ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. It markets and sells Hylenex recombinant, which is a formulation of rHuPH20. It markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Halozyme Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

38.57 USD

Average target price

50.5 USD

Spread / Average Target

+30.93%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
HALOZYME THERAPEUTICS, INC.	+4.36%	4.9B
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs